Drug
Eprenetapopt clinical trials
Also written APR-246 and PRIMA-1MET.
- studies test it
- 13
- open now
- 0
- in phase 3
- 1
- first study started
- 2009
How studies write it
Studies that test it under each name
Development codes
- APR-246
- 10
Combined with it in one product
Studies by the year they started
13 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2014 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 10
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 4
Aprea Therapeutics (9) · Groupe Francophone des Myelodysplasies (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Peter MacCallum Cancer Centre, Australia (1) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Azacitidine (4) · Venetoclax (2) · Liposomal doxorubicin (1) · Doxorubicin (1) · Dabrafenib (1)
Studies
Open first, then newest update. How each study uses eprenetapopt is read from its arms, and is right about nine times in ten.
Testing it · 13
- Study of the Safety and Efficacy of APR-246 in Combination With AzacitidineCompletedPhase 1/2Groupe Francophone des MyelodysplasiesNCT03588078Written as APR-246
- Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor MalignanciesCompletedPhase 1/2Aprea TherapeuticsNCT04383938Written as APR-246 (eprenetapopt) + Pembrolizumab
- APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)CompletedPhase 3Aprea TherapeuticsNCT03745716Written as APR-246 + azacitidine
- p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246CompletedPhase 2Aprea TherapeuticsNCT03268382Written as APR-246
- APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid MalignanciesCompletedPhase 1Aprea TherapeuticsNCT04214860Written as APR-246
- APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell TransplantCompletedPhase 2Aprea TherapeuticsNCT03931291Written as APR-246
- p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246CompletedPhase 1/2Aprea TherapeuticsNCT02098343Written as APR-246
- APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)TerminatedPhase 1/2Aprea TherapeuticsNCT04419389Written as APR-246 (eprenetapopt) + Acalabrutinib in CLL
- Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell LymphomaWithdrawnPhase 2M.D. Anderson Cancer CenterNCT04990778Written as Eprenetapopt
- Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid NeoplasmsCompletedPhase 1/2H. Lee Moffitt Cancer Center and Research InstituteNCT03072043Written as APR-246
- A Study of APR-246 in Oesophageal CancerTerminatedPhase 1/2Peter MacCallum Cancer Centre, AustraliaNCT02999893Written as APR-246
- Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate CancerCompletedPhase 1Aprea TherapeuticsNCT00900614Written as APR-246
- A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant MelanomaTerminatedPhase 1/2Aprea TherapeuticsNCT03391050Written as APR-246
Codes
What other systems call eprenetapopt · ClinicalTrials.gg INT005358
- MeSH (NLM) C533410eprenetapoptOne source NLM
- UNII (FDA) Z41TGB4080EPRENETAPOPTConfirmed FDA, NLM
- NCI Thesaurus C85465EprenetapoptOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C533410 | eprenetapopt | One source NLM |
| UNII (FDA) | Z41TGB4080 | EPRENETAPOPT | Confirmed FDA, NLM |
| NCI Thesaurus | C85465 | Eprenetapopt | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.